Unmet Needs in the Treatment of Multiple Myeloma
The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.
EP: 1.The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
EP: 2.Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM
EP: 3.Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM
EP: 4.Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
EP: 5.Assessing and Treating Patients with High-Risk NDMM
EP: 6.Treatment Approaches in Patients With Transplant-Ineligible NDMM
EP: 7.Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population
EP: 8.Available Treatment Options for Patients With R/R MM
EP: 9.Updated Results of the MonumenTAL-1 Study in R/R MM
EP: 10.Application of Bispecific Therapy in Clinical Practice
EP: 11.Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
EP: 12.Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
Now Viewing
EP: 13.Unmet Needs in the Treatment of Multiple Myeloma
EP: 14.Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
